NHS fast-track medicines pilots: what changes for pharma

Nine medicines have been approved under a NICE cost-effectiveness threshold that did not exist five months ago. Four pilot schemes begin testing this month, designed to move medicines from regulatory recommendation to NHS prescribing faster than the system currently manages. Both changes trace back to the UK-US pharmaceutical deal agreed in December 2025, under which the UK secured three years of zero US tariffs on pharmaceutical and medical technology exports in exchange for raising NHS medicines spending from 0.3% to 0.6% of GDP by 2036. For companies planning UK launches, the pilots look like the clearest signal yet that government wants medicines reaching patients faster, though similar promises have not always converted into faster prescribing.

The pilots also launch under a different health secretary from the one who announced them. James Murray unveiled the schemes in July while serving as health and social care secretary; within three weeks, Prime Minister Andy Burnham had moved Yvette Cooper into the role as part of his first cabinet reshuffle, a change CHASE covered in detail at the time. The pilots have carried over unchanged so far, but the department now delivering them is not the one that designed them.

What the four pilots test

The pilots target the gap between a NICE recommendation and a prescription reaching a patient. Each addresses a different part of that gap:

• Accelerated access lets treatments that meet safety and clinical standards reach eligible NHS patients before NICE completes a full appraisal, including therapies for rare conditions.

• A productivity valuation mechanism factors the economic value of patients returning to work into cost-effectiveness assessment, alongside the standard quality-adjusted life year calculation.

• Industry co-investment allows pharmaceutical companies to fund patient screening, testing and care pathway costs that would otherwise slow local adoption.

• Dedicated regional funding gives local health systems earmarked money to speed uptake of priority medicines.

Pharmaceutical companies can already fund some diagnostic and patient support activity under the ABPI Code; what the pilot appears to test is a standard national route for that investment, rather than trust-by-trust negotiation, though government has not yet published how the mechanism will work.

NICE estimates the combined effect of the threshold change and the pilots will support three to five additional medicine recommendations a year, on top of the nine already approved since April. Health Secretary James Murray framed the pilots at launch as removing unnecessary delay: "When a new medicine is proven to work, patients shouldn't have to wait." The industry response was similarly positive: ABPI chief executive Richard Torbett called the announcement "an important step toward making the UK world-leading for patient access and life sciences investment."

The deal behind them

The pilots exist because of a trade made eight months earlier. In December 2025, the UK agreed a pharmaceuticals arrangement with the US: zero tariffs on UK pharmaceutical and medtech exports, worth more than £5 billion a year, for a minimum of three years, in exchange for the UK doubling its innovative medicines spending as a share of GDP over the following decade and pursuing mutual recognition of medical device approvals. The arrangement is a political commitment rather than a binding treaty, which is why it bypassed the formal parliamentary scrutiny a trade agreement would normally receive.

Delivering on that commitment required changing how NICE decides what is cost-effective. In April 2026, NICE raised its threshold from £20,000-£30,000 to £25,000-£35,000 per quality-adjusted life year, the first revision in more than two decades. NICE chief executive Samantha Roberts framed the change as a political choice rather than a technical one: "In a health service funded by general taxation it is right that government decides on the level of health spend in the UK." Alongside the threshold change, the maximum rebate pharmaceutical companies pay under the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) was capped at 15% until the end of 2028. Some companies have already backed the arrangement with investment: Bristol Myers Squibb committed $500 million over five years, and UCB announced £500 million for UK research and manufacturing in January.

The funding dispute

Where that extra spending comes from is contested. A British Medical Journal analysis published in July by University of Liverpool professor Samuel Cross projected the arrangement could cost the NHS £44.7 billion cumulatively by 2036, rising from £1.3 billion in 2028 to £8.8 billion a year by then. If that sum is not matched by new funding and instead comes from reductions elsewhere in the NHS, the analysis estimated 229,000 excess deaths by 2036, concentrated in cardiovascular, respiratory, gastrointestinal and cancer care, rising to 291,000 once adult social care effects are included.

The government rejects the framing. The Department of Health argues the analysis wrongly assumes the money will come from cuts to frontline services, and Science Minister Lord Vallance has defended the deal as delivering "life-changing new medicines" while strengthening the life sciences sector. No impact assessment has been published, which the government attributes to commercial sensitivity. Two campaign groups, Just Treatment and Global Justice Now, have launched legal challenges arguing the changes lack a proper equalities assessment. Parliament's own scrutiny has been limited by the deal's structure: the Lords International Agreements Committee has asked why an arrangement of this scale was agreed as a memorandum of understanding rather than a treaty.

Approval and adoption

None of this dispute is about whether the pilots will work technically. It is about what happens once a medicine clears the new bar. On that question, the NHS's existing record offers more evidence than the pilots themselves.

NICE technology appraisal guidance already carries a statutory funding requirement: when NICE recommends a treatment "as an option," the NHS "must make sure it is available within 3 months (unless otherwise specified)" of publication. NICE's own guidance for tirzepatide, the weight-loss drug approved in December 2024, phased access deliberately: of the 3.4 million people in England estimated to meet the eligibility criteria, NICE and NHS England planned for only around 220,000, fewer than one in ten, to be treated within the first three years, prioritising patients already in specialist weight-management services before extending eligibility further. NICE built in the phasing because specialist service capacity could not absorb faster rollout, not because the mandate failed.

Medtech offers a comparable mechanism with a longer track record. The MedTech Funding Mandate carries a legal funding obligation similar to the medicines funding requirement, provided a technology has positive NICE guidance, demonstrates net savings within three years, and stays under a £20 million national budget impact. Since the mandate began in 2021, it has added twelve technologies in total, one of them, a knee osteoarthritis device, in the year to April 2025. No new technology has been added for 2026/27 while the policy sits under review and the mandate has existed for five years.  

Local variation compounds the problem. NICE guidance is meant to reach local formularies automatically within three months, but the King's Fund notes that "in practice, the picture is more complex": integrated medicines optimisation committees still assign their own local status to each medicine, and NHS England has committed to building a national dataset to measure how much that variation matters, because no baseline currently exists. It is the same variation that led NHS England to pilot a prototype single national formulary from June 2026, a separate reform aimed at the local end of the same pipeline these new pilots address at the national end.

What this means for commercial planning

The pilots address a real constraint. Getting a positive NICE recommendation faster, and getting paid for the infrastructure around it, removes a barrier that has stalled products in the past. But the evidence from tirzepatide and the MedTech Funding Mandate points to the same conclusion from two different mechanisms: a favourable national decision still sets a ceiling on how many patients can be treated, and specialist service capacity, workforce and local commissioning decide how close to that ceiling the NHS actually gets. Faster national approval does not speed up or expand any of those additional factors.

For launch planning, that argues for building implementation evidence into a submission alongside the clinical case:  

• Which trusts or regions have the specialist capacity a product depends on.  

• Which of those capacity gaps the industry co-investment pilot could plausibly fund, such as screening, testing or care pathway costs.  

• What employment or productivity data a business case will need ready if it wants to use the productivity valuation mechanism.

It also argues for watching the pilots' first cohort of medicines closely over the next year. If prescribing volumes match the tirzepatide pattern rather than the aspiration behind the pilots, that will tell a story about the limits of the fast-track approval route.

CHASE works with pharmaceutical and medtech companies on NHS market access, launch strategy and patient services delivery. Our insights team can help you assess where a product sits against these pilots and what implementation evidence its business case will need.